Azora Therapeutics is developing novel small molecule therapies targeting autoimmune and inflammatory diseases by harnessing the body's natural immune regulation. The company aims to provide effective treatment options for patients suffering from serious conditions, leveraging decades of drug development expertise.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many autoimmune and inflammatory diseases lack targeted and effective treatments, leaving patients with limited options to manage their conditions. Current therapies often have significant side effects or fail to address the underlying mechanisms of disease.
Solution
Azora Therapeutics is developing small molecule therapies designed to modulate the body's immune response for the treatment of autoimmune and inflammatory diseases. Their approach focuses on new chemical entities that can provide targeted intervention and improved efficacy. By harnessing the body's natural immune regulation, Azora aims to create treatments that are both effective and well-tolerated, addressing the unmet needs of patients with conditions like hidradenitis suppurativa (HS) and ulcerative colitis (UC). The company's lead compounds are designed to target key pathways involved in inflammation and immune dysregulation.
Target Audience
The primary target audience includes patients suffering from serious autoimmune and inflammatory diseases such as hidradenitis suppurativa and ulcerative colitis, as well as the physicians who treat them.
Features
- Development of novel small molecule new chemical entities (NCEs)
- Focus on oral AhR agonists for targeted immune modulation
- Clinical-stage programs for hidradenitis suppurativa (HS) and ulcerative colitis (UC)
- First generation oral AhR agonist demonstrated clinical response in Phase 1b study for treatment-refractory ulcerative colitis